BofA raised the firm’s price target on Teva to $15 from $14 and keeps a Buy rating on the shares. The firm, which forecasts Q4 sales and EBITDA that are slightly higher and roughly in-line versus consensus, respectively, cites a valuation multiple re-rate for its higher target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA: